Abstract
The basis for native as well as therapeutic neovascularization is not restricted to angiogenesis but includes postnatal vasculogenesis. Our laboratory and others' have established that bone marrow–derived endothelial progenitor cells (EPCs) are present in the systemic circulation, are augmented in response to certain cytokines and/or tissue ischemia, and home to as well as incorporate into sites of neovascularization. Given the background, EPCs have been investigated as therapeutic agents in these studies of supply-side angiogenesis under pathological as well as physiological conditions. This review discusses the therapeutic potential of EPCs for cardiovascular ischemic diseases.
Get full access to this article
View all access options for this article.